Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non Operating Income (2020 - 2025)

Mirum Pharmaceuticals has reported Non Operating Income over the past 6 years, most recently at -$218000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$218000.0 for Q4 2025, down 194.37% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 95.47% YoY), and the annual figure for FY2025 was $2.4 million, up 95.47%.
  • Non Operating Income for Q4 2025 was -$218000.0 at Mirum Pharmaceuticals, down from $395000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for MIRM hit a ceiling of $2.1 million in Q1 2025 and a floor of -$3.1 million in Q4 2023.
  • Median Non Operating Income over the past 5 years was -$26000.0 (2021), compared with a mean of $27150.0.
  • Biggest five-year swings in Non Operating Income: crashed 3358.82% in 2022 and later skyrocketed 788.54% in 2023.
  • Mirum Pharmaceuticals' Non Operating Income stood at -$17000.0 in 2021, then crashed by 3358.82% to -$588000.0 in 2022, then tumbled by 420.58% to -$3.1 million in 2023, then surged by 107.55% to $231000.0 in 2024, then plummeted by 194.37% to -$218000.0 in 2025.
  • The last three reported values for Non Operating Income were -$218000.0 (Q4 2025), $395000.0 (Q3 2025), and $86000.0 (Q2 2025) per Business Quant data.